New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 26, 2014
08:45 EDTANIKAnika Therapeutics price target raised to $60 from $47 at Summer Street
Summer Street raised its price target for Anika Therapeutics shares to $60 after the FDA approved Monovisc. The firm reiterates a Buy rating on the stock.
News For ANIK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 10, 2014
17:32 EDTANIKAnika Therapeutics announces CMS assigned J-Code to MONOVISC, effective Jan. 1
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use